CA2966487A1 - Nutraceutical supplement with lactobacillus rhamnosus - Google Patents
Nutraceutical supplement with lactobacillus rhamnosus Download PDFInfo
- Publication number
- CA2966487A1 CA2966487A1 CA2966487A CA2966487A CA2966487A1 CA 2966487 A1 CA2966487 A1 CA 2966487A1 CA 2966487 A CA2966487 A CA 2966487A CA 2966487 A CA2966487 A CA 2966487A CA 2966487 A1 CA2966487 A1 CA 2966487A1
- Authority
- CA
- Canada
- Prior art keywords
- extract
- dietary supplement
- ginger
- cells
- curcumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims description 34
- 239000013589 supplement Substances 0.000 title description 7
- 239000002417 nutraceutical Substances 0.000 title description 2
- 235000021436 nutraceutical agent Nutrition 0.000 title description 2
- 230000032683 aging Effects 0.000 claims abstract description 27
- 206010003246 arthritis Diseases 0.000 claims abstract description 26
- 230000036541 health Effects 0.000 claims abstract description 17
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 94
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 49
- 229940109262 curcumin Drugs 0.000 claims description 47
- 239000004148 curcumin Substances 0.000 claims description 47
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 47
- 239000000284 extract Substances 0.000 claims description 47
- 229930003316 Vitamin D Natural products 0.000 claims description 45
- 235000012754 curcumin Nutrition 0.000 claims description 45
- 235000019166 vitamin D Nutrition 0.000 claims description 45
- 239000011710 vitamin D Substances 0.000 claims description 45
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 45
- 229940046008 vitamin d Drugs 0.000 claims description 45
- 241000234314 Zingiber Species 0.000 claims description 42
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 42
- 235000008397 ginger Nutrition 0.000 claims description 42
- 240000007551 Boswellia serrata Species 0.000 claims description 41
- 235000018062 Boswellia Nutrition 0.000 claims description 39
- 230000000694 effects Effects 0.000 claims description 35
- 235000015872 dietary supplement Nutrition 0.000 claims description 28
- 235000020696 epimedium extract Nutrition 0.000 claims description 28
- 229940094952 green tea extract Drugs 0.000 claims description 26
- 235000020688 green tea extract Nutrition 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 230000000116 mitigating effect Effects 0.000 claims description 10
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 claims description 8
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims description 6
- 235000012035 Boswellia serrata Nutrition 0.000 claims description 6
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims description 6
- 230000000386 athletic effect Effects 0.000 claims description 6
- 229940030275 epigallocatechin gallate Drugs 0.000 claims description 6
- 230000037081 physical activity Effects 0.000 claims description 6
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 claims description 5
- 150000001765 catechin Chemical class 0.000 claims description 5
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 claims description 5
- 235000005487 catechin Nutrition 0.000 claims description 5
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 claims description 5
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 5
- 235000013824 polyphenols Nutrition 0.000 claims description 5
- 239000001841 zingiber officinale Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 229940102465 ginger root Drugs 0.000 claims description 3
- 241001362411 Epimedium sagittatum Species 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims description 2
- 235000006468 Thea sinensis Nutrition 0.000 claims description 2
- 235000020241 curcumin extract Nutrition 0.000 claims description 2
- 241001608538 Boswellia Species 0.000 claims 4
- 229940098324 green tea leaf extract Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 77
- 230000004054 inflammatory process Effects 0.000 abstract description 23
- 208000024891 symptom Diseases 0.000 abstract description 16
- 210000000130 stem cell Anatomy 0.000 abstract description 13
- 208000025978 Athletic injury Diseases 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 5
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 230000035876 healing Effects 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 235000017807 phytochemicals Nutrition 0.000 abstract 1
- 229930000223 plant secondary metabolite Natural products 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 62
- 241000186660 Lactobacillus Species 0.000 description 29
- 229940039696 lactobacillus Drugs 0.000 description 29
- 239000002775 capsule Substances 0.000 description 25
- 201000008482 osteoarthritis Diseases 0.000 description 25
- 239000004615 ingredient Substances 0.000 description 23
- 230000007423 decrease Effects 0.000 description 22
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 22
- 206010061218 Inflammation Diseases 0.000 description 20
- 230000006378 damage Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 230000011759 adipose tissue development Effects 0.000 description 18
- 239000003921 oil Substances 0.000 description 18
- 230000003078 antioxidant effect Effects 0.000 description 17
- 208000014674 injury Diseases 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 210000000845 cartilage Anatomy 0.000 description 13
- 230000001965 increasing effect Effects 0.000 description 13
- 230000002757 inflammatory effect Effects 0.000 description 13
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 12
- 210000001789 adipocyte Anatomy 0.000 description 12
- 230000003110 anti-inflammatory effect Effects 0.000 description 12
- 238000005516 engineering process Methods 0.000 description 12
- 102000046949 human MSC Human genes 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 11
- 239000012091 fetal bovine serum Substances 0.000 description 11
- 230000036542 oxidative stress Effects 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 206010039073 rheumatoid arthritis Diseases 0.000 description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 230000006872 improvement Effects 0.000 description 9
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- -1 coatings Substances 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 230000002293 adipogenic effect Effects 0.000 description 6
- 239000000556 agonist Substances 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 230000001857 anti-mycotic effect Effects 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 239000002543 antimycotic Substances 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 239000003925 fat Substances 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000005087 mononuclear cell Anatomy 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 208000000112 Myalgia Diseases 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000001503 joint Anatomy 0.000 description 5
- 238000002483 medication Methods 0.000 description 5
- 210000005036 nerve Anatomy 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000022159 cartilage development Effects 0.000 description 4
- 230000009816 chondrogenic differentiation Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229960003943 hypromellose Drugs 0.000 description 4
- 229960001680 ibuprofen Drugs 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 229960005489 paracetamol Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 210000002437 synoviocyte Anatomy 0.000 description 4
- 235000005282 vitamin D3 Nutrition 0.000 description 4
- 239000011647 vitamin D3 Substances 0.000 description 4
- 229940021056 vitamin d3 Drugs 0.000 description 4
- NBGQZFQREPIKMG-UHFFFAOYSA-N 3beta-hydroxy-beta-boswellic acid Natural products C1CC(O)C(C)(C(O)=O)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C NBGQZFQREPIKMG-UHFFFAOYSA-N 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- NBGQZFQREPIKMG-PONOSELZSA-N Boswellic acid Chemical compound C1C[C@@H](O)[C@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C NBGQZFQREPIKMG-PONOSELZSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- 206010017964 Gastrointestinal infection Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 229920001202 Inulin Polymers 0.000 description 3
- 208000003947 Knee Osteoarthritis Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000023178 Musculoskeletal disease Diseases 0.000 description 3
- 206010073713 Musculoskeletal injury Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000004067 Osteocalcin Human genes 0.000 description 3
- 108090000573 Osteocalcin Proteins 0.000 description 3
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 3
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 3
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 3
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000002449 bone cell Anatomy 0.000 description 3
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229940111134 coxibs Drugs 0.000 description 3
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 3
- 238000002784 cytotoxicity assay Methods 0.000 description 3
- 231100000263 cytotoxicity test Toxicity 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001627 detrimental effect Effects 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 239000000710 homodimer Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 3
- 229940029339 inulin Drugs 0.000 description 3
- 208000018937 joint inflammation Diseases 0.000 description 3
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 3
- 208000015001 muscle soreness Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000009818 osteogenic differentiation Effects 0.000 description 3
- 210000000578 peripheral nerve Anatomy 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 238000009662 stress testing Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- WJHZBTMHUNVIKC-UHFFFAOYSA-N valerylsalicylic acid Chemical compound CCCCC(=O)OC1=CC=CC=C1C(O)=O WJHZBTMHUNVIKC-UHFFFAOYSA-N 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 231100000747 viability assay Toxicity 0.000 description 3
- 238000003026 viability measurement method Methods 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- OSXBQXPUGBCPNS-GEHMVYPESA-N (5z,14z)-20-hydroxyicosa-5,14-dienoic acid Chemical compound OCCCCC\C=C/CCCCCCC\C=C/CCCC(O)=O OSXBQXPUGBCPNS-GEHMVYPESA-N 0.000 description 2
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 2
- 208000037411 Aortic calcification Diseases 0.000 description 2
- 241000209507 Camellia Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000034656 Contusions Diseases 0.000 description 2
- 208000012895 Gastric disease Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 206010051606 Necrotising colitis Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010041738 Sports injury Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 244000273928 Zingiber officinale Species 0.000 description 2
- 230000000181 anti-adherent effect Effects 0.000 description 2
- 230000002456 anti-arthritic effect Effects 0.000 description 2
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003911 antiadherent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000018597 common camellia Nutrition 0.000 description 2
- 229960001259 diclofenac Drugs 0.000 description 2
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000024765 knee pain Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000013465 muscle pain Diseases 0.000 description 2
- 230000009756 muscle regeneration Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 2
- 235000021590 normal diet Nutrition 0.000 description 2
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 2
- 230000003863 physical function Effects 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 108010067219 Aggrecans Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000001148 Cartilage Fractures Diseases 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- 229920002444 Exopolysaccharide Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010061223 Ligament injury Diseases 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010049565 Muscle fatigue Diseases 0.000 description 1
- 206010050031 Muscle strain Diseases 0.000 description 1
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 1
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 102000004722 NADPH Oxidases Human genes 0.000 description 1
- 108010002998 NADPH Oxidases Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 102000007365 Sialoglycoproteins Human genes 0.000 description 1
- 108010032838 Sialoglycoproteins Proteins 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 208000007156 Spondylarthritis Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000013201 Stress fracture Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 238000011666 aging animal model Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001188 articular cartilage Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000007211 cardiovascular event Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000003321 cartilage cell Anatomy 0.000 description 1
- 230000008355 cartilage degradation Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001700 effect on tissue Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 229910021485 fumed silica Inorganic materials 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000037231 joint health Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 229960000987 paricalcitol Drugs 0.000 description 1
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000004793 poor memory Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000001243 zingiber officinale rosc. root absolute Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/064342 WO2016072992A1 (en) | 2014-11-06 | 2014-11-06 | Nutraceutical supplement with lactobacillus rhamnosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2966487A1 true CA2966487A1 (en) | 2016-05-12 |
Family
ID=55909552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2966487A Abandoned CA2966487A1 (en) | 2014-11-06 | 2014-11-06 | Nutraceutical supplement with lactobacillus rhamnosus |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2017535289A (ko) |
| KR (1) | KR101971809B1 (ko) |
| CN (1) | CN107073062A (ko) |
| CA (1) | CA2966487A1 (ko) |
| WO (1) | WO2016072992A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210100866A1 (en) * | 2019-10-02 | 2021-04-08 | Lun Health Co. | Method of treatment using synergistic dietary supplements to relieve physical discomfort and pain, or mental discomfort linked to menstruation |
| EP3851115A1 (en) * | 2020-01-15 | 2021-07-21 | Biopolis, S.L. | Probiotic composition for its use as an antioxidant |
| JPWO2021201264A1 (ko) * | 2020-04-02 | 2021-10-07 | ||
| US11364255B2 (en) * | 2020-07-01 | 2022-06-21 | Karallief, Inc. | Therapeutic herbal compositions for improving joint health |
| CN112442463A (zh) * | 2020-11-25 | 2021-03-05 | 北京科拓恒通生物技术股份有限公司 | 鼠李糖乳杆菌Probio-M9及其制剂用于制备延长寿命制品的应用 |
| CN114098084A (zh) * | 2021-04-13 | 2022-03-01 | 中国人民解放军军事科学院军事医学研究院 | 一种缓解长期低剂量辐射暴露所致认知损伤的益生菌组合物及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5494668A (en) * | 1994-07-11 | 1996-02-27 | Patwardhan; Bhushan | Method of treating musculoskeletal disease and a novel composition therefor |
| US6123944A (en) * | 1998-03-19 | 2000-09-26 | Phytoceutica, Inc. | Icariin preparations |
| US6534086B1 (en) * | 2000-03-06 | 2003-03-18 | Metagenics, Inc. | Composition and method for treatment of inflammation and pain in mammals |
| US6492429B1 (en) * | 2000-07-10 | 2002-12-10 | N.V. Nutricia | Composition for the treatment of osteoarthritis |
| US20040037903A1 (en) * | 2001-06-13 | 2004-02-26 | Lemmo Edward A. | Phytonutrient formula for the relief of chronic pain resulting from inflammation |
| EP1325681A1 (en) * | 2001-12-11 | 2003-07-09 | Société des Produits Nestlé S.A. | Composition for promotion of bone growth and maintenance of bone health |
| CN1208072C (zh) * | 2002-11-19 | 2005-06-29 | 贵州神奇制药有限公司 | 治疗风湿、骨质疏松、骨质增生病的胶囊及其制备方法 |
| WO2007011674A2 (en) * | 2005-07-15 | 2007-01-25 | Baker Donald J | Compositions and methods for treating and preventing inflammatory and/or degenerative processes in humans and other animals |
| JP5162859B2 (ja) * | 2005-08-31 | 2013-03-13 | 大正製薬株式会社 | 眼精疲労の予防又は緩和剤 |
| US8017162B2 (en) | 2005-10-26 | 2011-09-13 | Oryza Oil & Fat Chemical Co., Ltd. | Anti-inflammatory agent |
| JP2007326839A (ja) * | 2006-06-06 | 2007-12-20 | Waccord:Kk | 糖尿病、歯周病および関節炎の改善を目的とする健康食品 |
| EP1961310A1 (en) * | 2007-02-01 | 2008-08-27 | DSMIP Assets B.V. | Novel use of (-) -epigallocatechin gallate |
| CA2682763A1 (en) * | 2007-03-27 | 2008-10-02 | The Procter & Gamble Company | Methods and kits for administering probiotics |
| US8029830B2 (en) * | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
| FI121952B (fi) * | 2009-05-06 | 2011-06-30 | Oriola Oy | Menetelmä pisaroina annosteltavan terveystuotteen valmistamiseksi |
| US8173181B2 (en) * | 2009-11-09 | 2012-05-08 | Bio-Engineered Supplements & Nutrition, Inc. | Method and composition for improved anabolism |
| CA2707721A1 (en) * | 2010-07-14 | 2010-09-21 | Nutritech Solutions Ltd. | Fermented milk beverage |
| JP6126443B2 (ja) * | 2012-06-08 | 2017-05-10 | 花王株式会社 | 骨格筋遅筋化剤 |
| CN104187710A (zh) * | 2014-07-28 | 2014-12-10 | 胡安然 | 炎性肠病全营养配方食品 |
-
2014
- 2014-11-06 CA CA2966487A patent/CA2966487A1/en not_active Abandoned
- 2014-11-06 KR KR1020177015272A patent/KR101971809B1/ko active IP Right Grant
- 2014-11-06 JP JP2017544271A patent/JP2017535289A/ja active Pending
- 2014-11-06 WO PCT/US2014/064342 patent/WO2016072992A1/en active Application Filing
- 2014-11-06 CN CN201480083170.9A patent/CN107073062A/zh not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN107073062A (zh) | 2017-08-18 |
| WO2016072992A1 (en) | 2016-05-12 |
| KR20170082576A (ko) | 2017-07-14 |
| KR101971809B1 (ko) | 2019-04-23 |
| JP2017535289A (ja) | 2017-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101971809B1 (ko) | 락토바실러스 람노서스를 보유한 기능식품 보충제 | |
| Kuptniratsaikul et al. | Efficacy and safety of Curcuma domestica extracts in patients with knee osteoarthritis | |
| Nakagawa et al. | Short-term effects of highly-bioavailable curcumin for treating knee osteoarthritis: a randomized, double-blind, placebo-controlled prospective study | |
| Lee et al. | Effects of Ficus carica paste on loperamide-induced constipation in rats | |
| US9468659B2 (en) | Nutraceutical supplement with Lactobacillus rhamnosus | |
| JP2019110899A (ja) | 軟骨破壊における使用のための組成物 | |
| US20110262552A1 (en) | Compositions Comprising Plant Extracts and Use Thereof for Treating Inflammation | |
| CN104188999A (zh) | 一种具有增加骨密度、改善骨骼及关节功能的组合物及其制备方法 | |
| Levy et al. | Flavocoxid is as effective as naproxen for managing the signs and symptoms of osteoarthritis of the knee in humans: a short-term randomized, double-blind pilot study | |
| Vaishya et al. | Current status of top 10 nutraceuticals used for Knee Osteoarthritis in India | |
| US20080031869A1 (en) | Pain relief composition | |
| Paudel et al. | Nutraceuticals and COVID‐19: a mechanistic approach toward attenuating the disease complications | |
| Zhou et al. | Safety evaluation of natural drugs in chronic skeletal disorders: a literature review of clinical trials in the past 20 years | |
| US20200113982A1 (en) | Composition and Uses Thereof | |
| US9980993B2 (en) | Nutraceutical supplement with Lactobacillus rhamnosus | |
| EP2701691B1 (en) | Composition for prevention and treatment of rheumatoid arthritis | |
| NAYAK et al. | Nutraceuticals as supplements in the management of arthritis: A review. | |
| EP2877203A1 (en) | Compositions for oral administration having a beneficial effect on tendinopathies and ligament injuries | |
| Staff | Nutraceutical Treatment in Knee Osteoarthritis—Arthritis-Presentation of a Dietary Plan by Means of Additional Nutraceuticals in Lieu of the Detrimental Side Effects of Current Conventional Medicine | |
| Ghoochani et al. | The Effects of pomegranate juice on proinflammatory cytokines and physical function in patients with knee osteoarthritis | |
| CN105012614A (zh) | 一种治疗膝关节骨性关节炎的中药外敷剂及护理方法 | |
| EP3810108A1 (en) | Composition for use in the prevention and/or treatment of osteoarticular diseases | |
| Alipoor et al. | Effect of arctium lappa L.(Burdock) root tea on clinical signs and symptoms in patients with knee osteoarthritis | |
| de Oliveira et al. | Analysis of the effects of curcumin and symbiotic consumption on bones of rats submitted to the use of dexamethasone | |
| Ansari et al. | Scientific study of Unani formulations In the cases of osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180208 |
|
| FZDE | Discontinued |
Effective date: 20191106 |